EP0714677A2 - Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation - Google Patents

Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation Download PDF

Info

Publication number
EP0714677A2
EP0714677A2 EP95308644A EP95308644A EP0714677A2 EP 0714677 A2 EP0714677 A2 EP 0714677A2 EP 95308644 A EP95308644 A EP 95308644A EP 95308644 A EP95308644 A EP 95308644A EP 0714677 A2 EP0714677 A2 EP 0714677A2
Authority
EP
European Patent Office
Prior art keywords
ventricular
pacing
rate
atrial
pacemaker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP95308644A
Other languages
German (de)
French (fr)
Other versions
EP0714677A3 (en
EP0714677B1 (en
Inventor
Saul Greenhut
Bruce Steinhaus
Albert Dawson
Tibor Nappholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacesetter Inc
Original Assignee
Telectronics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telectronics NV filed Critical Telectronics NV
Publication of EP0714677A2 publication Critical patent/EP0714677A2/en
Publication of EP0714677A3 publication Critical patent/EP0714677A3/en
Application granted granted Critical
Publication of EP0714677B1 publication Critical patent/EP0714677B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3621Heart stimulators for treating or preventing abnormally high heart rate
    • A61N1/3622Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/36514Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure
    • A61N1/36521Heart stimulators controlled by a physiological parameter, e.g. heart potential controlled by a physiological quantity other than heart potential, e.g. blood pressure the parameter being derived from measurement of an electrical impedance

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Electrotherapy Devices (AREA)

Abstract

A pacemaker is provided in which ventricular rate instabili ty is detected and automatically corrected by gradually increasing the ventricular pacing rate. Once the ventricle is stabilized, its pacing rate is gradually decreased as much as possible without losing ventricular stability. Ventricular instability can be a result of an atrial tachyrhythmia such as atrial fibrillation. Therefore, if the pacemaker is a dual chamber pacemaker, its operation is switched to a single chamber pacing mode thereby decoupling the ventricular pacing signals from the atrial pacing signals and atrial triggered ventricular pacing is inhibited until the atrial fibrillation terminates.

Description

    BACKGROUND OF THE INVENTION A. Field of Invention
  • The subject invention pertains to pacemakers, and more particularly to a pacemaker with means for stabilizing the ventricular rate, during atrial tachyrhythmia/fibrillation, by pacing the ventricle at successively higher rates until a steady state condition is established for the ventricle.
  • B. Description of the Invention
  • One problem experienced by some heart patients is a random depolarization or beat in the atrium, usually referred to as atrial fibrillation. Atrial fibrillation, while uncomfortable, does not constitute an immediate danger, by itself, to the patient and accordingly, the normal clinical approach to such a condition is to ignore it or to treat it in either an inadequate or a drastic manner. However, one indirect result of atrial fibrillation is an irregular ventricular rate. In other words, during atrial fibrillation, the ventricular intervals may vary substantially from one ventricular event to the next. The mechanism for this biological phenomenon is not understood completely. It has been suggested that, during atrial fibrillation, the AV node receives numerous successive stimuli originating from the atrium, and while each stimulus alone has a low amplitude which is insufficient to trigger a ventricular contraction, they do cause partial depolarizations. The effects of these partial depolarizations is cumulative, so that when a sufficient number of such stimuli are received, the AV node is depolarized resulting in unstable random ventricular contractions. (See R.J. Cohen et al, QUANTITATIVE MODEL FOR VENTRICULAR RESPONSE DURING ATRIAL FIBRILLATION, IEEE Transactions on Biomedical Engineering Volume 30, pages 769-782 (1983)). Ventricular instability is undesirable because it is uncomfortable for the patient. Presently, symptomatic patients are treated with drugs which are frequently ineffectual and/or have undesirable side effects or they are treated with AV nodal/ablation, a drastic procedure. However, stabilizing the ventricular rate during atrial fibrillation can lead to improved cardiac output, diastolic blood pressure, pulmonary artery pressure and end diastolic mitral valvular gradient. (C-P Lau, Leung, C-K Wong, Y-T Tai, C-H Cheng. A NEW PACING METHOD FOR RAPID REGULARIZATION OF RATE CONTROL IN ATRIAL FIBRILLATION, Am J Cardiol 65:1198-1203, (1990)).
  • It has been found that during atrial fibrillation, the ventricle can be stabilized at a rate approximately equal to the average intrinsic ventricular rate. Again, the mechanism of how the ventricle is stabilized by a pacing rate lower than the maximal intrinsic ventricular rate is not completely understood. It has been suggested that ventricular pacing eliminates the spontaneous depolarization phase of the AV node. F.H.M. Wittkampf, M.J.L. DeJongste, RATE STABILIZATION BY RIGHT VENTRICULAR PACING IN PATIENTS WITH ATRIAL FIBRILLATION. PACE 9:1147-1153 (1986). F.H.M. Wittkampf, M.J.L. DeJongste, H.I. Lie, F.L. Meigler. EFFECT OF RIGHT VENTRICULAR PACING ON VENTRICULAR RHYTHM DURING ATRIAL FIBRILLATION, J Am Coll Cardiol 11:539-545, (1988). These articles disclose that the ventricle may be stabilized by using 93-97% of the sensed and paced ventricular depolarizations for pacing. However this method would pace atrial flutter and atrial fibrillation with a regular ventricular response which would not be beneficial and result in overpacing. The proposed method provides a negative feedback (closed-loop control) on pacing and stability, whereas the previous method was open loop.
  • Another procedure (see Lau, supra) that was investigated to stabilize ventricular instability during atrial fibrillation was to apply an additional stimulus at a preselected interval after every sensed conducted ventricular beat. The average interval was about 230 ms. However it is believed that this procedure is unsatisfactory because it may result in proarrhythmia by pacing the ventricle during the vulnerable period of ventricular repolarization.
  • OBJECTIVES AND SUMMARY OF THE INVENTION
  • In view of the above, it is an objective of the present invention to provide a pacemaker which, during extended atrial fibrillation, automatically stabilizes ventricular pacing, to avoid discomfort and to insure a consistent blood flow for the patient.
  • A further objective is to provide a dual chamber pacemaker, which, in case of atrial fibrillation, automatically decouples ventricular pacing from the atrium and provide antiarrhythmic therapy until the ventricle is stabilized.
  • Yet another objective is to provide a pacemaker which is capable of automatically stabilizing the ventricle, and once the ventricle is stabilized, to reduce the ventricular pacing to the lowest level at which ventricle remains stable.
  • Yet a further objective is to provide a single chamber pacemaker which can detect atrial fibrillation and provide automatic antiarrhythmic therapy to the ventricle when atrial fibrillation is detected.
  • Other objectives and advantages of the invention shall become apparent from the following description of the invention. Briefly, a pacemaker constructed in accordance with this invention includes a pace and sense circuit providing interfacing with the outside world and a digital microprocessor receiving signals from the pace and sense circuit and providing, in response, control signals for cardiac pacing. The microprocessor detects atrial fibrillation and, in response, decouples the ventricular pacing from the atrium and provides stabilizing therapy to the ventricle-. More particularly, the microprocessor monitors the ventricle and, if its rate is unstable, it increases the ventricular pacing rate until the ventricle stabilizes. Once the ventricular rate stabilization is achieved, the microprocessor attempts to decrease the ventricular pacing rate while still maintaining stabilization.
  • In a dual chamber pacemaker operating in a DDD, DDDR, VDD or VDDR model, a monitor is provided, preferably implemented as software in the microprocessor, which monitors the atrial electrical activity to detect atrial tachyarrhythmias. When an atrial tachyarrhythmia is detected, the pacemaker is switched to single chamber (ventricle) pacing and, if necessary, the ventricle is stabilized as discussed above. When the atrial tachyarrhythmia ceases, the pacemaker resumes dual chamber operation.
  • In a single chamber ventricular pacemaker, atrial fibrillation is detected by other means, such as by monitoring the R-to-R wave interval variability. If this variability suddenly increases above an average value generated over a preselected number of past intervals, then atrial fibrillation is assumed.
    Alternatively, a measure of absolute variability and threshold can also be used for this purpose. Another means of detecting atrial fibrillation is to compare the intrinsic ventricular rate to a metabolic indicated rate, which is dependent on the actual cardiac demand. If the intrinsic pacing and metabolic indicated rate track each other, the patient is probably involved in an exercise which requires an increased cardiac output. However, if an intrinsic ventricular rate substantially exceeds the metabolic indicated rate, it is assumed that a tachy-arrhythmia is present, provided the patient does not suffer from ventricular tachyarrhymias.
  • BRIEF DESCRIPTION OF THE DRAWINGS
    • Figure 1 shows a block diagram of a pacemaker constructed in accordance with this invention;
    • Figure 2 shows a block diagram for the pace and sense circuit for the pacemaker of Figure 1;
    • Figure 3 shows a block diagram for the microprocessor of Figure 1;
    • Figure 4 shows a generalized flow chart for the microprocessor of Figure 3;
    • Figures 5A and 5B show a flow chart for a preferred embodiment of the invention;
    • Figure 6 shows a flow chart for an alternate embodiment of the invention;
    • Figure 7 shows a flow chart for another alternate embodiment for ventricular stabilization in a single chamber ventricular pacemaker; and
    • Figure 8 shows another flow chart for ventricular stabilization with a single ventricular chamber device.
    DETAILED DESCRIPTION OF THE INVENTION
  • Referring now to Figure 1, a pacemaker 10 constructed in accordance with this invention includes an implantable housing 12. The housing holds a pace and sense circuit 14, described in more detail in Figure 2, and a microprocessor 16, described in more detail in Figure 3. The pace and sense circuit 14 and the microprocessor 16 are interconnected by a bus 18 for exchanging data, as well as communication and control signals. The pacemaker 10 further includes a memory 20 connected to the microprocessor 16 by a data and address bus 22, and a power supply 24 providing power to the various components of pacemaker 10 via power bus 26.
  • Once implanted, the pacemaker 10 is connected to a patient's heart 28 by two leads 30, 32. Preferably, these leads 30, 32 are bi-polar leads with lead 30 being connected to the atrial chamber of the heart, and lead 32 being connected to the ventricular chamber. Therefore leads 30 and 32 are known as the atrial cardiac lead and the ventricular cardiac lead, respectively. It should be understood that the arrangement of the pacemaker 10 and leads 30 and 32 do not form a part of this invention. Other arrangements may be used as well, using other types of leads including tri-polar leads, unipolar leads and so on. In some embodiments, lead 30 may be absent or may only sense (not pace). For example, in VDD mode lead 30 may be used as a "single-pass" lead.
  • Referring now to Figure 2, the pace and sense control circuit 14 includes a bus interface 36, a telemetry circuit 38 and various other sensing and control circuits for sensing the status of the chambers of heart 28 and to provide appropriate pacing signals thereto. The bus interface 36 provides interfacing with microprocessor 16 via bus 18. The telemetry circuit 38 provides communication with the outside world by, for example, RF. Signals with the telemetry circuit are exchanged via telemetering bus 40.
  • More specifically, signals from the atrium are sensed through lead 30 by the atrial heartbeat sensor 42. This sensor 42 is controlled by the atrial sense control bus 44. Atrial pacing pulses are generated for lead 30 by atrial pacing pulse generator 46. This generator is controlled by the atrial pacing control bus 48. Similarly, the ventricular chamber is sensed through lead 32 by ventricular heartbeat sensor 50, which is controlled by a ventricular sense control bus 52. Pacing pulses for the ventricular chamber are generated by the ventricular pacing pulse generator 54, controlled by the ventricular pacing control bus 56.
  • In addition, the impedance of the heart tissues are measured through one of the cardiac leads, such as lead 32, by impedance measurement circuit 58. This circuit is controlled by impedance control bus 60. All the control buses are interconnected between their respective circuits and the bus interface 36 to provide two way communication with the microprocessor 16.
  • Referring now to Figure 3, the microprocessor 16 includes a bus interface circuit 62 for interfacing with bus 18, and an internal bus 64 interconnecting the various components of the microprocessor 16. The microprocessor 16 further includes a read only memory (ROM) 66 used for storing programming information, a random access memory (RAM) 68 used as a scratch pad, a pacing calculator 70, a metabolic indicated rate (MIR) calculator 72, and an atrial rate monitor 74.
  • Except as noted below, the operation of the pacemaker 10 illustrated in Figures 1-3 is described in commonly assigned copending application SN 226,654, Filed on April 12, 1994 by T. A. Nappholz, entitled FORCED ATRIO-VENTRICULAR SYNCHRONY DUAL CHAMBER PACEMAKER, and incorporated herein by reference. Briefly, the impedance of the tissues of the heart 28 is measured by impedance measurement circuit 58 at regular intervals. These sequential measurements are transmitted via control bus 60, bus 18 and internal bus 64 (through the interface circuits 36 and 62) to the MIR calculator 72. This calculator 72 converts these impedance measurements into a minute volume corresponding to the patient's metabolic oxygen demand. Of course, any other Rate Responsive Sensor could be used for the purposes of this application. This minute volume is in turn transformed into a metabolic indicated rate (MIR) and transmitted to the pacing calculator 70. The pacing calculator 70 also receives information regarding the sensing and/or pacing of the atrial and/or ventricular chambers of heart 28 through the respective sensors 42, 50. Based on the received information, the calculator 70 generates pacing control signals for pacing the heart in a particular mode. These control signals are transmitted to the pacing pulse generators 46 and 54 which in response generate appropriate pacing pulses to the ventricle and atrium as described above.
  • The operation of the microprocessor 16 for correcting the ventricular response to atrial tachyarrhythmias shall now be described in conjunction with the flow chart of Figure 4. Initially, in step S100, the microprocessor 16 operates the pacemaker 10 in a standard pacing mode such as DDDX (i.e. DDD or DDDR) or VDDX (i.e. VDD or VDDR). As part of this mode of operation, the atrial rate is monitored by monitor 74 through sensor 42 and/or 58 to detect atrial tachyarrhythmias such-as fibrillation (AF). This may be accomplished by various methods including comparing the atrial rate to a threshold level, using waveform morphology, or a hemodynamic parameter, or comparison between the metabolic indicated rate (MIR) and the intrinsic atrial and/or ventricular rates. If an atrial fibrillation is detected by monitor 74, the microprocessor 16 enters into a ventriclar rate stabilization mode. In this mode, in step S104, the monitor 74 sends a signal on line 76 to the pacing calculator 70 to reset the pacing to a different mode, such as DDIX or VDIX. Next, in step S106, the monitor 74 selects a new ventricular pacing rate as described more fully below and sends this new rate on line 78 to the pacing calculator 70.
  • In step S108, the monitor 74 determines whether the ventricular rate for all is stabilized. If the ventricular rate is not stabilized, the monitor reverts to step S106.
  • Ventricular rate stability can be found using a number of different methods. For example the interval between two R waves (standard in the pacemaker field) can be measured and the stability of this parameter may be defined in terms of statistical variance, standard deviation, rate mean squared difference, normalized mean absolute deviation, normalized approximate interquartile range, autocorrelation, Markov chains, coefficient of variation, histograms, using maximum, average, and minimum values stored in a look-up table, or a normalized mean absolute difference, discussed below.
  • Steps S106 and S108 are repeated until an optimum ventricular pacing rate is found for which the ventricle is stabilized.
  • After this optimum rate is found, the microprocessor 16 continues to operate in the mode selected in step S104 at the ventricular rate defined in step S106. As indicated in step S110 the monitor 74 continues to monitor the atrium to determine when the atrial tachyrhythmia has terminated. This function is not sequenced with others but is always on. When the atrial tachyrhythmia is no longer detected, monitor 74 orders the calculator 70 to switch back to the original mode (Step 112) and this original mode of operation is resumed in step S100.
  • As previously mentioned, the stability of the ventricle can be established using a number of different methods. One method which is particularly advantageous is a so-called normalized mean absolute difference method described in detail below. This method is preferred because it is not very complex and hence can be easily implemented, and yet it has the ability to discriminate ventricular stability.
  • Briefly, as part of this method, the sequential intervals RR are first measured between adjacent R waves sensed in the ventricle. After i such intervals are measured and assigned sequential designations RR1, RR2, RR3,... RRi, the mean absolute difference parameter MADIFF is calculated using the formula:
    Figure imgb0001
  • The numerator of this expression is obtained by taking the difference between adjacent RRi intervals and summing N of these differences. The denominator of this expression is obtained by adding N adjacent intervals RRi. Dividing the sum of the differences by the sum of the intervals results in a parameter MADIFF, which is a normalized mean value for N intervals. This value MADIFF indicates the average variation of the intervals from an average interval after N intervals have taken place.
  • The parameter MADIFF is then compared to a preset threshold value. This threshold level may be for example 0.1 or 10%. A parameter value MADIFF which exceeds this threshold level is indicative of ventricular activity which is random and unstable. Therefore, the pacing rate is increased by a small amount D1 from the pacing rate used just prior to the detection of AF. D1, for example, may be 5ppm. The whole process is repeated with this new pacing rate until a pacing rate is achieved for which the MADIFF parameter is below the threshold, indicating that the ventricle has stabilized. Pacing of the ventricle continues with calculated ventricular at the last pacing rate.
  • It is preferable to pace the ventricle at the lowest rate possible while still maintaining ventricular rate stability. Because the patient's condition may change (i.e. lower level of catecholima), it has been observed that ventricular rate stability is subject to a hysteresis effect. Therefore, after ventricular rate stability is achieved at a higher rate, it is possible to decrease the rate and still maintain stability. Hence, after stability has been achieved, the parameter MADIFF can be adjusted further for successive intervals i. After a predetermined number of intervals have passed, during which the ventricle has remained stable, a new pace rate may be set, for example, by lowering the old pace rate by a preset amount D2. D2 may be, for example, 5 ppm. If in the next N intervals, the ventricle remains stable, the new pacing rate is maintained. Otherwise, the pacing rate is increased by amount D2 and the calculation is repeated for the next N intervals until the ventricle is stabilized again.
  • The method described above can be implemented as shown in Figures 5A and 5B. Starting with Figure 5A, step S200 is performed after a pathological atrial tachyrhythmia has been detected and the pacemaker has been switched to a new pacing mode as shown in Figure 4, step S104. In step 200, the variable StR indicates the current pacing rate and initially is set to either the ventricular stability rate (non-R modes) or MIR (R modes). Variable K is set to zero. The variable StR is adjusted up and down, as set forth below, until the lowest pacing rate is found at which the ventricle is stable. The variable K is used to count the number of intervals during which the ventricle is stable. In step 202 the variables i, RRd, and RRt are set to zero. Variable i is the variable used to count the number of intervals RRi, the variable RRd is used for the sum of the absolute differences RRi+1-RRi and the variable RRt is used to calculate the sum of the intervals RRi as i progresses from 0 to N.
  • Steps S204 and S206 are shown as occurring sequentially but in fact they are performed together. In step S206 the interval RRi is measured. This step is accomplished, by first detecting an R wave and, then, waiting for the next R wave to occur. During this waiting time, the condition of the atrium is monitored in step S204 and if the atrial tachyrhythmia ceases, the microprocessor cycles back to step S112 in figure 4.
  • Once an interval RRi is determined, the microprocessor proceeds to step S208 where this interval RRi is added to the previous value of RRt thereby updating the latter. In step S210 a check is performed to determine if interval RRi is the first interval of a series of N intervals that has been measured. The reason for this check is that for the first interval RR0 there is no difference RRd to be calculated.
  • If i=0, then in steps S212 and S214 the variables i and K are incremented. In step S216 a check is performed to see if K has reached a predetermined value, such as 127. If K has not reached this value, the microprocessor cycles back to step 204 and the next measurement RR1 is obtained.
  • After the second measurement RR1 is obtained, since i>0, the microprocessor cycles from step S210 to step 218 where the difference variable RRd is updated. In the following step S220, a check is performed to determine if a predetermined number of intervals, such as 8 in Figure 5A, have been measured. If not, then the microprocessor cycles back to step S212 for incrementing i and K and measuring the next RRi.
  • The embodiment of Figures 5A and 5B is designed for stabilizing the ventricle of a person at rest. After the preset number of intervals RRi have been measured (8 in Fig. 5A), the microprocessor proceeds to step S222 (Figure 5B). In this step, a check is performed to determine if the current pacing rate StR exceeds a preset threshold such as 90 ppm. The purpose of this check is to insure that the rate StR does not exceed this threshold. The threshold of 90 ppm has been selected because it is believed that it is a safe upper limit for pacing a person at rest.
  • After the check in step S222, in step S224 the parameter MADIFF is calculated as defined above. In the following step S226 a check is made to determine if the parameter MADIFF is below a preset level such as 0.1. As previously discussed, if this parameter is above the preset threshold level, the ventricle pacing is not stable. Therefore in step S228 the pacing rate StR is increased by 5 ppm. In the following step S230, the variable K is reset to zero since, obviously, the ventricle has not been stabilized yet. The microprocessor then cycles to step S232 (Figure 5A) discussed below.
  • Importantly, at step S226 if the parameter MADIFF is below the preset threshold (i.e., 0.1), the pace StR is not changed and the variable K is not reset, before cycling to step S232.
  • Going back to step S216 (Figure 5A) when a sufficient number of intervals RRi have been measured without changing the pacing rate StR, i.e., when K reaches 127, the microprocessor proceeds to step S234 where the pacing rate StR is reduced by 5ppm. In the following step S236, the variable K is reset to zero, and the microprocessor then goes on to step S232.
  • In step S232, the different variables, such as StR and MADIFF are stored in a memory for future data analysis, if required. The microprocessor then proceeds to step S202 where the whole cycle starts over again.
  • It should be understood that the various values preset in Figures 5A and 5B for the various checks, i.e. in steps S210, S220, and so forth as well as the increments for increasing and decreasing StR are only exemplary and that other values may also be used.
  • As previously described, the embodiment of Figures 5A and 5B are designed for a person at rest with a pacing rate limited to 90 ppm. For a person performing some kind of exercise, the embodiment of these Figures may be modified by replacing step S222 (Figure 5B) with the steps S222A, S222B and S222C shown in Figure 6. It will be recalled that one of the control parameters used by the pacing calculator 70 in Figure 3 is a metabolic indicated rate (MIR) derived by calculator 72 (Figure 3). In Figure 6, the value of StR is checked to determine if it exceeds the metabolic indicated rate MIR. The metabolic indicated rate is dependant on the physiological demand of the patient's body and hence it is or could be related to other stress level related to the exercise level of the patient. In step S222A a check is performed to see if the current rate StR has exceeded MIR by a preset level such as 30 ppm. If the rate StR has reached this level, then the microprocessor recycles to step S232 without any changes to the rate StR. Step S222B is provided to insure that the rate StR did not somehow exceed either the level set in step S222A (i.e., MIR + 30 ppm) or a maximum allowable pacing rate MAXRATE set for the patient. If the rate StR has exceeded these limits, then in step S222C the rate StR is decreased by 5 ppm and the microprocessor returns to step S236 (Figure 5A). If the rate StR does not exceed the limits of step S222B then the microprocessor goes on to step S224 in Figure 5B for calculating the parameter MADIFF. From then on the microprocessor proceeds as discussed above.
  • In the above-described embodiments, the control parameter used to make a determination about the stability of the ventricular rate is RRi, defined as the interval between two adjacent R waves. Alternatively, the control parameter could be the interval between n R waves where n could be an integer greater than one. In other words, the control parameter is the time interval between two non-adjacent R waves. This alternative may be used to reduce the sensitivity of the apparatus to premature ventricular depolarizations.
  • Figures 4-6 and the description for these figures pertains to the preferred embodiments of the invention, and more particularly to a method and apparatus for stabilizing the ventricle during atrial fibrillation in association with a dual chamber pacemaker. Of course, the method and apparatus of stabilizing the ventricle can be used for other purposes as well. For example, in Figure 7, a flow chart is illustrated for a single chamber pacemaker. Initially the pacemaker is operating in a VVIX mode at a pacing rate VR derived from ventricular sensing, as indicated by step S300. In this mode, since atrial sensing is not available, another means must be found to sense atrial fibrillation. For example, the RRi interval may be measured in step S302. In the following step 304, the parameter MADIFF is determined based on several sequential RRi measurements in accordance with the procedure set forth above. In step S306 a check is performed to determine if the parameter MADIFF is above a preselected constant C. As previously indicated, the MADIFF parameter provides a quantitative measure of the rate stability of the ventricle. A source of instability of the ventricle is atrial fibrillation. Therefore, the check in step S306 is performed to detect ventricle instability due to the atrial fibrillation. However for this check, the constant C must be larger than in the determination of Figure 5 step S226, because, for step S226 the assumption can be made that normal sinus rhythm is not present. This assumption cannot be made for step S306. A preferred value of C is about 0.3, i.e. 30% of the average value of RR.
  • If the calculated value of MADIFF exceeds C, it is assumed that the atrium is undergoing fibrillation, and accordingly in step S308 the rate VR is periodically modified (i.e. incremented by 5 ppm) until the ventricle is stabilized, i.e. the parameter MADIFF falls below 0.1. The process for stabilizing the ventricle is described above, and in the flow chart of Figures 5A and 5B.
  • If, in step S306, the parameter MADIFF is below C, the pacing continues at rate VR.
  • An alternate embodiment to Figure 7 is shown in Figure 8. In this Figure, in step S400 the pacemaker is operating in mode VVIX. At regular intervals, the intrinsic rate IR is measured in step S402. This rate is compared to the metabolic indicated rate (MIR) discussed above. The MIR parameter indicates the metabolic demand of the patient's body and therefore it is an accurate representation of the patient's exercise level. If the intrinsic rate (IR) increases while the MIR remains about the same, it is probable that the increase in IR is due to a pathological atrial tachyrhythmia if the patient is not suceptible to ventricular arrhythmias. Therefore, in step S402, if the difference between IR and MIR is greater than a preselected constant D, an atrial tachyrhythmia is assumed and in step S406 the pacing rate is adjusted in accordance with Figure 7. Constant D may be, for example, 30 ppm. A % change could also be used, such as; 100 x IR-MIR MIR > E
    Figure imgb0002
  • where E is a preselected threshold.
  • The embodiments of Figures 7 and 8 are useful for providing a separate trigger indicative of atrial arrhythmia for example for a patient suffering for paroxysmal episodes of atrial fibrillation. For a patient with chronic atrial fibrillation, the trigger is unnecessary and the pacing rate may be adjusted constantly to eliminate ventricular instability in accordance with the process set forth in Figures 4, 5A, 5B.
  • In patients with a fast ventricular response to AF the electrical therapy described could be combined with a relatively low dose of drug (e.g. beta blocker), so that the ventricular rate for stability during rest is not too high (< 90ppm).
  • Although the invention has been described with reference to several particular embodiments, it is to be understood that these embodiments are merely illustrative of the application of the principles of the invention. Accordingly, the embodiments described in particular should be considered exemplary, not limiting, with respect to the following claims.

Claims (15)

  1. An implantable pacemaker for insertion into a patient for stimulating the heart, said pacemaker comprising:
    means for pacing the ventricle at an induced ventricular pacing rate;
    means for detecting an atrial tachyarrhymia;
    means for increasing said induced pacing rate gradually until ventricular response of atrial tachyarrhymia is stabilized.
  2. The pacemaker of claim 1 further comprises means for decreasing said induced pacing rate gradually while maintaining cardiac stability.
  3. The pacemaker of claim 1 further comprising means for detecting an atrial fibrillation of said heart.
  4. The pacemaker of claim 3 further comprising means for pacing the atrium at an atrial pacing rate, said atrial pacing means being disabled when said atrial fibrillation is detected.
  5. The pacemaker of claim 1 wherein said detecting means includes means for detecting a plurality of intervals RRi between R waves, means for determining normalized value for said RRi and means for determining when said normalized value exceeds a preselected threshold.
  6. The pacemaker of claim 1 further comprising means for generating a metabolic indicated rate, said means for detecting ventricular instability including means for comparing said metabolic indicated rate with the intrinsic ventricular pacing.
  7. A pacemaker implantable in a patient for stimulating the heart, said pacemaker comprising:
    means for generating atrial induced pacing signals for pacing the atrium;
    means for generating ventricular induced pacing signals for pacing the ventricle, in a normal mode of operation said ventricular induced signals being coupled to said atrial induced pacing signals;
    means for detecting atrial tachyrhythmia; and
    means for increasing said ventricular induced pacing signals gradually until the ventricular rate is stabilized.
  8. The pacemaker of claim 7 further comprising means for detecting said atrial fibrillation.
  9. The pacemaker of claim 8 further comprising decoupling means for decoupling said ventricular induced pacing signals from said atrial induced pacing signals when the atrial fibrillation is detected.
  10. The pacemaker of claim 7 wherein said detecting means includes means for measuring an interval between adjacent intrinsic ventricular signals and comprising means for comparing said intervals to a threshold level.
  11. A method of providing pacing signals to a heart with an implanted pacemaker, said method comprising the steps of:
    applying ventricular pacing signals to the ventricle;
    monitoring the atrium to determine atrial instability wherein the atrium exhibits random atrial beats; and
    increasing the rate of said ventricular pacing signals gradually until ventricular rate stability is achieved.
  12. The method of claim 11 further comprising the step of decreasing said rate while maintaining ventricular stability.
  13. The method of claim 11 wherein said atrial fibrillation is determined by monitoring the atrium.
  14. The method of claim 11 wherein said atrial fibrillation is determined by comparing an intrinsic ventricular signal rate to a metabolic indicated rate.
  15. The method of claim 11 wherein said atrial instability is determined by measuring an interval between intrinsic ventricular signals.
EP95308644A 1994-11-30 1995-11-30 Apparatus for stabilizing the ventricular rate of a heart during atrial fibrillation Expired - Lifetime EP0714677B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US347279 1994-11-30
US08/347,279 US5480413A (en) 1994-11-30 1994-11-30 Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation

Publications (3)

Publication Number Publication Date
EP0714677A2 true EP0714677A2 (en) 1996-06-05
EP0714677A3 EP0714677A3 (en) 1998-04-01
EP0714677B1 EP0714677B1 (en) 2004-07-14

Family

ID=23363068

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95308644A Expired - Lifetime EP0714677B1 (en) 1994-11-30 1995-11-30 Apparatus for stabilizing the ventricular rate of a heart during atrial fibrillation

Country Status (3)

Country Link
US (2) US5480413A (en)
EP (1) EP0714677B1 (en)
DE (1) DE69533251T2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071576A1 (en) * 2003-02-05 2004-08-26 Medtronic, Inc. Atrial fibrillation detection via a ventricular lead

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136019A (en) * 1996-08-19 2000-10-24 Mower Family Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool
US6343232B1 (en) 1966-08-19 2002-01-29 Mower Chf Treatment Irrevocable Trust Augmentation of muscle contractility by biphasic stimulation
US6141587A (en) * 1996-08-19 2000-10-31 Mower Family Chf Treatment Irrevocable Trust Augmentation of muscle contractility by biphasic stimulation
US5480413A (en) * 1994-11-30 1996-01-02 Telectronics Pacing Systems, Inc. Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation
US5643327A (en) * 1995-06-20 1997-07-01 Pacesetter, Inc. Pacemaker and method having optimized A-V delay by using the evoked depolarization potential as an indicia of cardiac output
US5690681A (en) * 1996-03-29 1997-11-25 Purdue Research Foundation Method and apparatus using vagal stimulation for control of ventricular rate during atrial fibrillation
US5713929A (en) * 1996-05-03 1998-02-03 Medtronic, Inc. Arrhythmia and fibrillation prevention pacemaker using ratchet up and decay modes of operation
US7840264B1 (en) 1996-08-19 2010-11-23 Mr3 Medical, Llc System and method for breaking reentry circuits by cooling cardiac tissue
US7440800B2 (en) * 1996-08-19 2008-10-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US6178351B1 (en) 1996-08-19 2001-01-23 The Mower Family Chf Treatment Irrevocable Trust Atrial sensing and multiple site stimulation as intervention means for atrial fibrillation
US8447399B2 (en) * 1996-08-19 2013-05-21 Mr3 Medical, Llc System and method for managing detrimental cardiac remodeling
US6295470B1 (en) 1996-08-19 2001-09-25 The Mower Family Chf Treatment Irrevocable Trust Antitachycardial pacing
US7203537B2 (en) 1996-08-19 2007-04-10 Mr3 Medical, Llc System and method for breaking reentry circuits by cooling cardiac tissue
US6141586A (en) * 1996-08-19 2000-10-31 Mower Family Chf Treatment Irrevocable Trust Method and apparatus to allow cyclic pacing at an average rate just above the intrinsic heart rate so as to maximize inotropic pacing effects at minimal heart rates
US6411847B1 (en) 1996-08-19 2002-06-25 Morton M. Mower Apparatus for applying cyclic pacing at an average rate just above the intrinsic heart rate
US7908003B1 (en) 1996-08-19 2011-03-15 Mr3 Medical Llc System and method for treating ischemia by improving cardiac efficiency
US6337995B1 (en) 1996-08-19 2002-01-08 Mower Chf Treatment Irrevocable Trust Atrial sensing and multiple site stimulation as intervention for atrial fibrillation
US6341235B1 (en) 1996-08-19 2002-01-22 Mower Chf Treatment Irrevocable Trust Augmentation of electrical conduction and contractility by biphasic cardiac pacing administered via the cardiac blood pool
US5792193A (en) * 1996-11-05 1998-08-11 Vitatron Medical, B.V. Pacemaker system and method with ventricular rate smoothing during high rate atrial arrhythmia
US5846263A (en) 1996-12-13 1998-12-08 Medtronic, Inc. Apparatus for diagnosis and treatment of arrhythmias
US5893882A (en) * 1996-12-17 1999-04-13 Medtronic, Inc. Method and apparatus for diagnosis and treatment of arrhythmias
US5814085A (en) 1996-12-19 1998-09-29 Medtronic, Inc. Rate stabilization pacemaker
US5817134A (en) * 1997-02-25 1998-10-06 Greenhut; Saul E. Apparatus and method for detecting atrial fibrillation by morphological analysis
US5840079A (en) 1997-03-27 1998-11-24 Medtronic, Inc. Method and apparatus for treatment of atrial fibrillation
US5978707A (en) 1997-04-30 1999-11-02 Cardiac Pacemakers, Inc. Apparatus and method for treating ventricular tachyarrhythmias
US6112117A (en) * 1997-05-06 2000-08-29 Cardiac Pacemakers, Inc. Method and apparatus for treating cardiac arrhythmia using electrogram features
FR2763247B1 (en) * 1997-05-16 2000-02-18 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR A CARDIAC STIMULATOR, DEFIBRILLATOR AND / OR CARDIOVERTER FOR REDUCING ARRHYTHMIA EPISODES, ESPECIALLY ATRIAL ARRHYTHMIA
US5853426A (en) * 1997-06-02 1998-12-29 Pacesetter, Inc. Method and apparatus for delivering atrial defibrillaton therapy with improved effectiveness
US5999850A (en) * 1997-07-21 1999-12-07 Pacesetter, Inc. Pacemaker with safe R-wave synchronization during countershock conversion of atrial fibrillation
US5836985A (en) * 1997-09-18 1998-11-17 The Regents Of The University Of Michigan Method for treating abnormal arial or ventricular activity
US5951592A (en) * 1997-11-21 1999-09-14 Pacesetter, Inc. Apparatus and method for applying antitachycardia therapy based on ventricular stability
US6067470A (en) * 1998-03-05 2000-05-23 Mower Family Chf Treatment Irrevocable Trust System and method for multiple site biphasic stimulation to revert ventricular arrhythmias
US6556862B2 (en) * 1998-03-19 2003-04-29 Cardiac Pacemakers, Inc. Method and apparatus for treating supraventricular tachyarrhythmias
EP0985428A1 (en) 1998-08-12 2000-03-15 Pacesetter, Inc. A pacemaker with safe r-wave synchronization during countershock conversion of atrial fibrillation
US6047210A (en) 1998-09-03 2000-04-04 Cardiac Pacemakers, Inc. Cardioverter and method for cardioverting an atrial tachyarrhythmia while maintaining atrial pacing
US6528856B1 (en) * 1998-12-15 2003-03-04 Intel Corporation High dielectric constant metal oxide gate dielectrics
US6434424B1 (en) * 1998-12-28 2002-08-13 Medtronic, Inc. Regularization of ventricular rate during atrial tachyarrhythmia
US6411845B1 (en) 1999-03-04 2002-06-25 Mower Chf Treatment Irrevocable Trust System for multiple site biphasic stimulation to revert ventricular arrhythmias
US6256537B1 (en) 1999-03-17 2001-07-03 Medtronic, Inc. Pacemaker system with inhibition of AV node for rate regulation during atrial fibrillation
US7203535B1 (en) 1999-04-01 2007-04-10 Cardiac Pacemakers, Inc. System and method for classifying tachycardia arrhythmias having 1:1 atrial-to-ventricular rhythms
US6298267B1 (en) 1999-04-30 2001-10-02 Intermedics Inc. Method and apparatus for treatment of cardiac electromechanical dissociation
US6195584B1 (en) 1999-04-30 2001-02-27 Medtronic, Inc. Method and apparatus for determining atrial lead dislocation
US6263241B1 (en) 1999-04-30 2001-07-17 Intermedics, Inc. Method and apparatus for treatment of cardiac electromechanical dissociation
US7062325B1 (en) * 1999-05-21 2006-06-13 Cardiac Pacemakers Inc Method and apparatus for treating irregular ventricular contractions such as during atrial arrhythmia
US6351669B1 (en) 1999-05-21 2002-02-26 Cardiac Pacemakers, Inc. Cardiac rhythm management system promoting atrial pacing
US7142918B2 (en) * 2000-12-26 2006-11-28 Cardiac Pacemakers, Inc. Apparatus and method for pacing mode switching during atrial tachyarrhythmias
US6285907B1 (en) 1999-05-21 2001-09-04 Cardiac Pacemakers, Inc. System providing ventricular pacing and biventricular coordination
US8064997B2 (en) * 1999-05-21 2011-11-22 Cardiac Pacemakers, Inc. Method and apparatus for treating irregular ventricular contractions such as during atrial arrhythmia
US7181278B2 (en) * 1999-05-21 2007-02-20 Cardiac Pacemakers, Inc. Apparatus and method for ventricular rate regularization
US7212860B2 (en) * 1999-05-21 2007-05-01 Cardiac Pacemakers, Inc. Apparatus and method for pacing mode switching during atrial tachyarrhythmias
US6430438B1 (en) 1999-05-21 2002-08-06 Cardiac Pacemakers, Inc. Cardiac rhythm management system with atrial shock timing optimization
US6501988B2 (en) 2000-12-26 2002-12-31 Cardiac Pacemakers Inc. Apparatus and method for ventricular rate regularization with biventricular sensing
US6270457B1 (en) 1999-06-03 2001-08-07 Cardiac Intelligence Corp. System and method for automated collection and analysis of regularly retrieved patient information for remote patient care
US6607485B2 (en) 1999-06-03 2003-08-19 Cardiac Intelligence Corporation Computer readable storage medium containing code for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care
US6312378B1 (en) 1999-06-03 2001-11-06 Cardiac Intelligence Corporation System and method for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care
US7134996B2 (en) * 1999-06-03 2006-11-14 Cardiac Intelligence Corporation System and method for collection and analysis of patient information for automated remote patient care
US7429243B2 (en) * 1999-06-03 2008-09-30 Cardiac Intelligence Corporation System and method for transacting an automated patient communications session
US6221011B1 (en) 1999-07-26 2001-04-24 Cardiac Intelligence Corporation System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system
CA2314513A1 (en) * 1999-07-26 2001-01-26 Gust H. Bardy System and method for providing normalized voice feedback from an individual patient in an automated collection and analysis patient care system
CA2314517A1 (en) * 1999-07-26 2001-01-26 Gust H. Bardy System and method for determining a reference baseline of individual patient status for use in an automated collection and analysis patient care system
US6440066B1 (en) 1999-11-16 2002-08-27 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for ordering and prioritizing multiple health disorders to identify an index disorder
US6336903B1 (en) * 1999-11-16 2002-01-08 Cardiac Intelligence Corp. Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes thereof
US6411840B1 (en) * 1999-11-16 2002-06-25 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring the outcomes of atrial fibrillation
US8369937B2 (en) 1999-11-16 2013-02-05 Cardiac Pacemakers, Inc. System and method for prioritizing medical conditions
US6368284B1 (en) 1999-11-16 2002-04-09 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring myocardial ischemia and outcomes thereof
US6398728B1 (en) * 1999-11-16 2002-06-04 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring respiratory insufficiency and outcomes thereof
US7308306B1 (en) * 1999-12-23 2007-12-11 Pacesetter, Inc. System and method for dynamic ventricular overdrive pacing
US6671548B1 (en) 1999-12-29 2003-12-30 Pacesetter, Inc. Implantable stimulation device and method for discrimination atrial and ventricular arrhythmias
US6496731B1 (en) * 2000-04-14 2002-12-17 Cardiac Pacemakers, Inc. Highly specific technique for discriminating atrial fibrillation from atrial flutter
US7239914B2 (en) * 2000-05-13 2007-07-03 Cardiac Pacemakers, Inc. Rate smoothing control
US7039461B1 (en) * 2000-05-13 2006-05-02 Cardiac Pacemakers, Inc. Cardiac pacing system for prevention of ventricular fibrillation and ventricular tachycardia episode
US6522925B1 (en) 2000-05-13 2003-02-18 Cardiac Pacemakers, Inc. System and method for detection enhancement programming
US6501987B1 (en) 2000-05-26 2002-12-31 Cardiac Pacemakers, Inc. Rate smoothing control
US6721596B1 (en) 2000-05-15 2004-04-13 Cardiac Pacemakers, Inc. Atrial shock therapy with ventricular pacing
US6847842B1 (en) 2000-05-15 2005-01-25 Cardiac Pacemakers, Inc. Method and apparatus for reducing early recurrence of atrial fibrillation with defibrillation shock therapy
US8512220B2 (en) * 2000-05-26 2013-08-20 Cardiac Pacemakers, Inc. Rate smoothing control
FR2809630B1 (en) * 2000-06-05 2003-01-24 Ela Medical Sa ACTIVE IMPLANTABLE MEDICAL DEVICE SUCH AS A CARDIAC STIMULATOR, DEFIBRILLATOR, CARDIOVERTER AND / OR MULTISITE DEVICE WITH IMPROVED DETECTION OF LATE EXTRASYSTOLES
US6424865B1 (en) 2000-07-13 2002-07-23 Cardiac Pacemakers, Inc. Ventricular conduction delay trending system and method
US6704597B1 (en) * 2000-07-20 2004-03-09 Cardiac Pacemakers, Inc. Apparatus and method for energy management in atrial defibrillator
US6512951B1 (en) 2000-09-14 2003-01-28 Cardiac Pacemakers, Inc. Delivery of atrial defibrillation shock based on estimated QT interval
US6829504B1 (en) 2000-09-14 2004-12-07 Cardiac Pacemakers, Inc. System and method for preventing recurrence of atrial tachyarrhythmia
WO2002024068A1 (en) 2000-09-20 2002-03-28 Mcgill University Method and system for detection of cardiac arrhythmia
US7369890B2 (en) * 2000-11-02 2008-05-06 Cardiac Pacemakers, Inc. Technique for discriminating between coordinated and uncoordinated cardiac rhythms
US6978177B1 (en) * 2000-11-14 2005-12-20 Cardiac Pacemakers, Inc. Method and apparatus for using atrial discrimination algorithms to determine optimal pacing therapy and therapy timing
JP4119751B2 (en) 2000-11-28 2008-07-16 メドトロニック・インコーポレーテッド Implantable medical devices
US6689117B2 (en) * 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
US6957100B2 (en) 2000-12-26 2005-10-18 Cardiac Pacemakers, Inc. Method and system for display of cardiac event intervals in a resynchronization pacemaker
US20020087198A1 (en) 2000-12-29 2002-07-04 Kramer Andrew P. Apparatus and method for ventricular rate regularization
DE60141349D1 (en) * 2000-12-26 2010-04-01 Cardiac Pacemakers Inc DEVICE FOR REGULATING THE VENTRICULAR HEART RATE
US6963776B2 (en) * 2001-04-05 2005-11-08 Cardiac Pacemakers, Inc. Cardiac rhythm management system synchronizing atrial shock to ventricular depolarization based on length of sensing refractory
US6584350B2 (en) 2001-04-06 2003-06-24 Cardiac Pacemakers, Inc. Apparatus and method for R-wave detection with dual dynamic sensitivities
US6748267B2 (en) * 2001-07-25 2004-06-08 Biotronik Mess-Und Therapiegeraete Gmbh & Co. Heart therapy device
US7050852B2 (en) * 2001-09-24 2006-05-23 Cardiac Pacemakers, Inc. Pacemaker mode switching based upon atrial conduction time
US7340303B2 (en) * 2001-09-25 2008-03-04 Cardiac Pacemakers, Inc. Evoked response sensing for ischemia detection
US6748269B2 (en) * 2001-10-17 2004-06-08 Cardiac Pacemakers, Inc. Algorithm for discrimination of 1:1 tachycardias
US6907286B1 (en) * 2001-10-19 2005-06-14 Pacesetter, Inc. Anti-tachycardia pacing methods and devices
US6668195B2 (en) 2001-10-30 2003-12-23 Medtronic, Inc. Methods and apparatus for reducing the likelihood of atrial fibrillation
KR100415114B1 (en) * 2001-11-28 2004-01-13 삼성전자주식회사 Apparatus and method for voice multiplexing in asynchronous transfer mode network supporting voice and data service
US6909916B2 (en) * 2001-12-20 2005-06-21 Cardiac Pacemakers, Inc. Cardiac rhythm management system with arrhythmia classification and electrode selection
US7146206B2 (en) 2002-03-20 2006-12-05 Medtronic, Inc. Detection of cardiac arrhythmia using mathematical representation of standard ΔRR probability density histograms
US7158827B2 (en) * 2002-04-22 2007-01-02 Medtronic, Inc. Ventricular rate stabilization
US7072711B2 (en) 2002-11-12 2006-07-04 Cardiac Pacemakers, Inc. Implantable device for delivering cardiac drug therapy
US7627373B2 (en) * 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US20040158289A1 (en) * 2002-11-30 2004-08-12 Girouard Steven D. Method and apparatus for cell and electrical therapy of living tissue
US7009511B2 (en) 2002-12-17 2006-03-07 Cardiac Pacemakers, Inc. Repeater device for communications with an implantable medical device
US7181277B1 (en) * 2003-03-11 2007-02-20 Pacesetter, Inc. Methods and systems for reducing the likelihood of arrhythmia onset
US20040215257A1 (en) * 2003-04-25 2004-10-28 Van Oort Geeske Ventricular rate stabilization with cardiac resynchronization
US7536224B2 (en) * 2003-04-30 2009-05-19 Medtronic, Inc. Method for elimination of ventricular pro-arrhythmic effect caused by atrial therapy
US7751892B2 (en) * 2003-05-07 2010-07-06 Cardiac Pacemakers, Inc. Implantable medical device programming apparatus having a graphical user interface
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
US20050137626A1 (en) * 2003-12-19 2005-06-23 Pastore Joseph M. Drug delivery system and method employing external drug delivery device in conjunction with computer network
US8025624B2 (en) * 2004-02-19 2011-09-27 Cardiac Pacemakers, Inc. System and method for assessing cardiac performance through cardiac vibration monitoring
US7488290B1 (en) * 2004-02-19 2009-02-10 Cardiac Pacemakers, Inc. System and method for assessing cardiac performance through transcardiac impedance monitoring
US7532929B2 (en) 2004-02-23 2009-05-12 Biotronik Crm Patent Ag Adaptive ventricular rate smoothing during atrial fibrillation
US7593772B2 (en) * 2004-04-30 2009-09-22 Lawrence Duane Sherman Methods and devices to characterize the probability of successful defibrillation and determine treatments for ventricular fibrillation
US20060025931A1 (en) * 2004-07-30 2006-02-02 Richard Rosen Method and apparatus for real time predictive modeling for chronically ill patients
US7329226B1 (en) 2004-07-06 2008-02-12 Cardiac Pacemakers, Inc. System and method for assessing pulmonary performance through transthoracic impedance monitoring
US7228176B2 (en) * 2004-07-22 2007-06-05 Cardiac Pacemakers, Inc. Systems, devices, and methods for tachyarrhythmia discrimination or therapy decisions
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8874204B2 (en) * 2004-12-20 2014-10-28 Cardiac Pacemakers, Inc. Implantable medical devices comprising isolated extracellular matrix
US8332030B2 (en) * 2005-04-27 2012-12-11 Medtronic, Inc. Device and method for providing atrial-synchronized ventricular pacing with selective atrial tracking
US8781847B2 (en) * 2005-05-03 2014-07-15 Cardiac Pacemakers, Inc. System and method for managing alert notifications in an automated patient management system
US20100063840A1 (en) * 2005-05-03 2010-03-11 Hoyme Kenneth P System and method for managing coordination of collected patient data in an automated patient management system
US20060253300A1 (en) * 2005-05-03 2006-11-09 Somberg Benjamin L System and method for managing patient triage in an automated patient management system
US20060276716A1 (en) * 2005-06-07 2006-12-07 Jennifer Healey Atrial fibrillation detection method and apparatus
US7634310B2 (en) * 2006-10-30 2009-12-15 Medtronic, Inc. Method and apparatus for atrial fibrillation detection based on ventricular cycle lengths
US8706224B1 (en) 2007-10-30 2014-04-22 Pacesetter, In. Systems and methods for paired/coupled pacing and dynamic overdrive/underdrive pacing
US8818510B2 (en) * 2007-10-30 2014-08-26 Pacesetter, Inc. Systems and methods for paired/coupled pacing
US8934971B1 (en) 2007-11-14 2015-01-13 Pacesetter, Inc. Implantable cardiac stimulation device and method that stabilizes ventricular rate during episodes of atrial fibrillation
WO2009075749A1 (en) * 2007-12-11 2009-06-18 Cardiac Pacemakers, Inc. Lv unipolar sensing or pacing vector
WO2009075725A1 (en) 2007-12-13 2009-06-18 Cardiac Pacemakers, Inc. Supraventricular tachy sensing vector
WO2009124187A1 (en) * 2008-04-04 2009-10-08 Draeger Medical Systems, Inc. A cardiac condition detection system
EP2299907B1 (en) * 2008-06-02 2015-02-11 Medtronic, Inc. Discrimination of ventricular tachycardia from supraventricular tachycardia
DE102008002293A1 (en) * 2008-06-09 2009-12-10 Biotronik Crm Patent Ag Anti-tachycardia cardiac stimulator
US8340765B2 (en) * 2009-03-24 2012-12-25 Pacesetter, Inc. System and method for controlling ventricular pacing during AF based on underlying ventricular rates using an implantable medical device
US8239011B2 (en) * 2009-04-29 2012-08-07 Cardiac Pacemakers, Inc. Atrial arrhythmia detection and discrimination based on intracardiac impedance
US10220213B2 (en) 2015-02-06 2019-03-05 Cardiac Pacemakers, Inc. Systems and methods for safe delivery of electrical stimulation therapy
US11235163B2 (en) 2017-09-20 2022-02-01 Cardiac Pacemakers, Inc. Implantable medical device with multiple modes of operation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016258A1 (en) * 1991-03-15 1992-10-01 Medtronic, Inc. Dual chamber rate responsive pacemaker with automatic mode switching

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4998974A (en) * 1990-01-05 1991-03-12 Telectronics Pacing Systems, Inc. Apparatus and method for antitachycardia pacing in dual chamber arrhythmia control system
US5193536A (en) * 1990-12-20 1993-03-16 Medtronic, Inc. Paced cardioversion
US5312453A (en) * 1992-05-11 1994-05-17 Medtronic, Inc. Rate responsive cardiac pacemaker and method for work-modulating pacing rate deceleration
DE69307509T2 (en) * 1992-06-30 1997-07-31 Medtronic Inc DEVICE FOR THE TREATMENT OF HEART ERRORS
US5282836A (en) * 1992-10-23 1994-02-01 Incontrol, Inc. Atrial defibrillator and method for providing pre-cardioversion pacing
US5411524A (en) * 1993-11-02 1995-05-02 Medtronic, Inc. Method and apparatus for synchronization of atrial defibrillation pulses
US5480413A (en) * 1994-11-30 1996-01-02 Telectronics Pacing Systems, Inc. Apparatus and method for stabilizing the ventricular rate of a heart during atrial fibrillation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016258A1 (en) * 1991-03-15 1992-10-01 Medtronic, Inc. Dual chamber rate responsive pacemaker with automatic mode switching

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WITTKAMPF F.H.M AND DE JONGSTE M.J.L: "Rate Stabilization by Right Ventricular Pacing in Patients with Atrial Fibrillation" PACE, vol. 9, 1 November 1986, pages 1147-1153, XP000562479 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071576A1 (en) * 2003-02-05 2004-08-26 Medtronic, Inc. Atrial fibrillation detection via a ventricular lead

Also Published As

Publication number Publication date
DE69533251T2 (en) 2005-07-28
DE69533251D1 (en) 2004-08-19
US5591215A (en) 1997-01-07
EP0714677A3 (en) 1998-04-01
EP0714677B1 (en) 2004-07-14
US5480413A (en) 1996-01-02

Similar Documents

Publication Publication Date Title
EP0714677B1 (en) Apparatus for stabilizing the ventricular rate of a heart during atrial fibrillation
US6595927B2 (en) Method and system for diagnosing and administering therapy of pulmonary congestion
EP0615770B1 (en) Apparatus for managing and monitoring cardiac rhythm using active time as the controlling parameter
US5999850A (en) Pacemaker with safe R-wave synchronization during countershock conversion of atrial fibrillation
US6615083B2 (en) Implantable medical device system with sensor for hemodynamic stability and method of use
US6823213B1 (en) Implantable medical device and method using integrated T-wave alternans analyzer
US7869877B2 (en) Cardiopulmonary functional status assessment via heart rate response detection by implantable cardiac device
US5161527A (en) Apparatus and method for detecting abnormal cardiac rhythms in dual chamber arrhythmia control system
US6526311B2 (en) System and method for sensing and detecting far-field R-wave
US6514195B1 (en) Ischemic heart disease detection
US6694189B2 (en) Rate adaptive pacemaker system with dual sensing component and method of using same
US6580946B2 (en) Pressure-modulated rate-responsive cardiac pacing
JP4689143B2 (en) Monitoring device for implantation in the patient&#39;s body
US6754532B1 (en) Coronary sinus flow regulated pacing
US20040230242A1 (en) Pacemaker post pace artifact discriminator
US6650938B2 (en) Method and system for preventing atrial fibrillation by rapid pacing intervention
US6721599B2 (en) Pacemaker with sudden rate drop detection based on QT variations
EP1617898B1 (en) Pacemaker with improved capability for detecting onset of tachyarrhythmias and heart failure
EP1453571B1 (en) Rate responsive pacing system with qt sensor based on intrinsic qt data
US8761881B2 (en) Intracardiac polarization signal stabilization
EP0985428A1 (en) A pacemaker with safe r-wave synchronization during countershock conversion of atrial fibrillation
EP1585577A2 (en) Ventricular rate stablization

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951215

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): DE FR GB

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): DE FR GB

17Q First examination report despatched

Effective date: 20021017

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PACESETTER, INC.

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: APPARATUS FOR STABILIZING THE VENTRICULAR RATE OF A HEART DURING ATRIAL FIBRILLATION

RTI1 Title (correction)

Free format text: APPARATUS FOR STABILIZING THE VENTRICULAR RATE OF A HEART DURING ATRIAL FIBRILLATION

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): DE FR GB

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69533251

Country of ref document: DE

Date of ref document: 20040819

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20041130

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050415

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20041130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20091201

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101130

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20131127

Year of fee payment: 19

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69533251

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150602